Tekmira Joins International Consortium in Developing RNAi-Based Ebola Therapy
The Wellcome Trust awarded £3.2 million to the consortium to manufacture an RNAi-based Ebola therapy and to begin clinical trials in West African treatment centers.
Tekmira Pharmaceuticals Corporation, a developer of RNA interference (RNAi) therapeutics, announced on Sept. 23, 2014 that it will collaborate with an international consortium to provide an RNAi-based investigational therapeutic for expedited clinical studies in West Africa.
The consortium includes representatives from many organizations including WHO, US Centers for Disease Control, Médecins Sans Frontières - Doctors without Borders (MSF), ISARIC, and Fondation Mérieux.
The Wellcome Trust awarded £3.2 million (approximately $5.2 million USD) to the consortium to fund the manufacture of investigational therapeutics as well as the establishment of an operational clinical trials platform in two or more Ebola virus disease (EVD) treatment centers in West Africa.
The clinical trials will assess the efficacy and safety of promising therapeutics and vaccines to treat patients with EVD.
Tekmira will use the genetic sequence of the Ebola virus variant responsible for the ongoing outbreak in West Africa to design an RNAi-based product to specifically target this viral strain.
Source: Tekmira
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
